LMO1 intracellular antibody fragments for delivery in improved treatment of childhood neuroblastoma
Lead Research Organisation:
Institute of Cancer Research
Department Name: Division of Cancer Therapeutics
Abstract
The LIM-only protein LMO1 is implicated in neuroblastoma by synergising with MYCN to promote tumour development and metastasis. The proposed work will use technologies we developed to isolate an inhibitory intracellular antibody and, in turn Antibody-derived (Abd) compounds, for the LMO1 paralogue LMO2. The anti-LMO1 intracellular antibody will be used in mouse models of neuroblastoma for studies of cooperative oncogenicity with MYCN, in parallel with compound library screening for LMO1-binding Abd compounds. The reagents and compounds will have a major impact on neuroblastoma treatment.
People |
ORCID iD |
Studentship Projects
| Project Reference | Relationship | Related To | Start | End | Student Name |
|---|---|---|---|---|---|
| MR/W006553/1 | 30/09/2022 | 29/09/2030 | |||
| 2933515 | Studentship | MR/W006553/1 | 06/10/2024 | 05/10/2028 |